Trial Outcomes & Findings for The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen (NCT NCT00999466)

Results Overview

Forced Expiratory Volume in 1 second (FEV1), Late Asthmatic Response (LAR), is derived as the ratio of FEV1 Area Under Curve 4-10 hour post allergen challenge (AUC 4-10h) (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

60 participants

Primary outcome timeframe

Pre-treatment (Baseline measurement)

Results posted on

2016-02-26

Participant Flow

Participant milestones

Participant milestones
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Pilot Part STARTED	6	0	3
Pilot Part COMPLETED	6	0	3
Pilot Part NOT COMPLETED	0	0	0
Main Part STARTED	0	26	25
Main Part COMPLETED	0	22	21
Main Part NOT COMPLETED	0	4	4

Reasons for withdrawal

Reasons for withdrawal
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Main Part Withdrawal by Subject	0	0	2
Main Part Adverse Event	0	4	2

Baseline Characteristics

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	AZD8848, 30 μg n=6 Participants AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=26 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=28 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.	Total n=60 Participants Total of all reporting groups
Age, Continuous	36.3 Years n=5 Participants	33.0 Years n=7 Participants	32.3 Years n=5 Participants	33.9 Years n=4 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	7 Participants n=7 Participants	7 Participants n=5 Participants	14 Participants n=4 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	19 Participants n=7 Participants	21 Participants n=5 Participants	46 Participants n=4 Participants

PRIMARY outcome

Timeframe: Pre-treatment (Baseline measurement)

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Forced Expiratory Volume in 1 second (FEV1), Late Asthmatic Response (LAR), is derived as the ratio of FEV1 Area Under Curve 4-10 hour post allergen challenge (AUC 4-10h) (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=23 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
FEV1, Late Asthmatic Response (LAR) - Pre-treatment	—	0.814 ratio Standard Deviation 0.450	1.01 ratio Standard Deviation 0.784

PRIMARY outcome

Timeframe: 1 week after last dose

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

FEV1, Late Asthmatic Response (LAR), is derived as the ratio of FEV1 AUC 4-10h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=23 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
FEV1, Late Asthmatic Response (LAR) - 1 Week After Last Dose	—	0.616 ratio Standard Deviation 0.296	0.970 ratio Standard Deviation 0.641

PRIMARY outcome

Timeframe: 4 weeks after last dose

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

FEV1, Late Asthmatic Response (LAR), is derived as the ratio of FEV1 AUC 4-10h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=21 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
FEV1, Late Asthmatic Response (LAR) - 4 Weeks After Last Dose	—	0.759 ratio Standard Deviation 0.397	0.722 ratio Standard Deviation 0.584

SECONDARY outcome

Timeframe: Pre-treatment (Baseline measurement)

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

FEV1, Early Asthmatic Response (EAR), is derived as the ratio of FEV1 Area Under Curve 0-2 hour post allergen challenge (AUC 0-2h) (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=23 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
FEV1, Early Asthmatic Response (EAR) - Pre-treatment	—	0.524 ratio Standard Deviation 0.241	0.611 ratio Standard Deviation 0.362

SECONDARY outcome

Timeframe: 1 week after last dose

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

FEV1, Early Asthmatic Response (EAR), is derived as the ratio of FEV1 AUC 0-2h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=23 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
FEV1, Early Asthmatic Response (EAR) - 1 Week After Last Dose	—	0.468 ratio Standard Deviation 0.361	0.624 ratio Standard Deviation 0.362

SECONDARY outcome

Timeframe: 4 weeks after last dose

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

FEV1, Early Asthmatic Response (EAR), is derived as the ratio of FEV1 AUC 0-2h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=21 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
FEV1, Early Asthmatic Response (EAR) - 4 Weeks After Last Dose	—	0.510 ratio Standard Deviation 0.240	0.591 ratio Standard Deviation 0.401

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=23 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
PC20 Methacholine Challenge - Pre-treatment, Pre Allergen Challenge	—	0.564 mg/mL Interval 0.004 to 11.1	0.609 mg/mL Interval 0.063 to 5.69

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=23 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
PC20 Methacholine Challenge - Pre-treatment, Post Allergen Challenge	—	0.425 mg/mL Interval 0.123 to 6.25	0.364 mg/mL Interval 0.063 to 10.2

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=21 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
PC20 Methacholine Challenge - 1 Week After Last Dose, Pre Allergen Challenge	—	0.488 mg/mL Interval 0.063 to 3.01	0.454 mg/mL Interval 0.063 to 8.25

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=21 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=21 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
PC20 Methacholine Challenge - 1 Week After Last Dose, Post Allergen Challenge	—	0.691 mg/mL Interval 0.063 to 9.13	0.340 mg/mL Interval 0.063 to 17.8

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=22 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=21 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
PC20 Methacholine Challenge - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.468 mg/mL Interval 0.063 to 2.47	0.504 mg/mL Interval 0.072 to 4.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=21 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=20 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
PC20 Methacholine Challenge - 4 Weeks After Last Dose, Post Allergen Challenge	—	0.326 mg/mL Interval 0.082 to 4.08	0.508 mg/mL Interval 0.063 to 29.1

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Tumour Necrosis Factor Alpha (TNFα) - Pre-treatment, Pre Allergen Challenge	—	8.9 pg/mL Interval 3.5 to 25.0	4.8 pg/mL Interval 0.9 to 24.0

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, TNFα - Pre-treatment, Post Allergen Challenge	—	13 pg/mL Interval 2.8 to 156.0	12 pg/mL Interval 5.3 to 38.0

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, TNFα - 1 Week After Last Dose, Pre Allergen Challenge	—	6.5 pg/mL Interval 1.7 to 46.0	5.3 pg/mL Interval 0.9 to 23.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, TNFα - 1 Week After Last Dose, Post Allergen Challenge	—	11 pg/mL Interval 2.4 to 539.0	8.4 pg/mL Interval 1.1 to 41.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, TNFα - 4 Weeks After Last Dose, Pre Allergen Challenge	—	5.1 pg/mL Interval 0.9 to 113.0	9.4 pg/mL Interval 1.5 to 510.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, TNFα - 4 Weeks After Last Dose, Post Allergen Challenge	—	13 pg/mL Interval 4.3 to 125.0	7.9 pg/mL Interval 4.4 to 23.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Interleukin-1β (IL-1β) - Pre-treatment, Pre Allergen Challenge	—	37 pg/mL Interval 6.5 to 127.0	23 pg/mL Interval 0.8 to 243.0

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-1β - Pre-treatment, Post Allergen Challenge	—	41 pg/mL Interval 13.0 to 322.0	44 pg/mL Interval 13.0 to 320.0

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-1β - 1 Week After Last Dose, Pre Allergen Challenge	—	37 pg/mL Interval 7.8 to 614.0	36 pg/mL Interval 4.5 to 139.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-1β - 1 Week After Last Dose, Post Allergen Challenge	—	45 pg/mL Interval 7.0 to 293.0	37 pg/mL Interval 13.0 to 217.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-1β - 4 Weeks After Last Dose, Pre Allergen Challenge	—	29 pg/mL Interval 6.6 to 303.0	43 pg/mL Interval 7.6 to 366.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-1β - 4 Weeks After Last Dose, Post Allergen Challenge	—	72 pg/mL Interval 15.0 to 198.0	41 pg/mL Interval 15.0 to 224.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Interleukin-5 (IL-5) - Pre-treatment, Pre Allergen Challenge	—	0.83 pg/mL Interval 0.4 to 9.0	0.87 pg/mL Interval 0.4 to 5.6

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-5 - Pre-treatment, Post Allergen Challenge	—	7.1 pg/mL Interval 0.4 to 74.0	5.8 pg/mL Interval 0.4 to 27.0

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-5 - 1 Week After Last Dose, Pre Allergen Challenge	—	0.82 pg/mL Interval 0.4 to 4.5	1.3 pg/mL Interval 0.4 to 11.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-5 - 1 Week After Last Dose, Post Allergen Challenge	—	7.8 pg/mL Interval 1.1 to 38.0	5.4 pg/mL Interval 0.9 to 35.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-5 - 4 Weeks After Last Dose, Pre Allergen Challenge	—	1.2 pg/mL Interval 0.4 to 5.5	1.7 pg/mL Interval 0.4 to 24.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-5 - 4 Weeks After Last Dose, Post Allergen Challenge	—	5.7 pg/mL Interval 0.8 to 38.0	8.0 pg/mL Interval 2.1 to 47.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Interleukin-6 (IL-6) - Pre-treatment, Pre Allergen Challenge	—	15 pg/mL Interval 4.4 to 61.0	9.4 pg/mL Interval 0.4 to 189.0

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-6 - Pre-treatment, Post Allergen Challenge	—	28 pg/mL Interval 5.7 to 252.0	27 pg/mL Interval 1.7 to 75.0

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-6 - 1 Week After Last Dose, Pre Allergen Challenge	—	15 pg/mL Interval 2.4 to 43.0	9.6 pg/mL Interval 0.4 to 37.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-6 - 1 Week After Last Dose, Post Allergen Challenge	—	26 pg/mL Interval 5.2 to 142.0	23 pg/mL Interval 3.1 to 76.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-6 - 4 Weeks After Last Dose, Pre Allergen Challenge	—	12 pg/mL Interval 0.6 to 123.0	21 pg/mL Interval 6.3 to 1317.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-6 - 4 Weeks After Last Dose, Post Allergen Challenge	—	20 pg/mL Interval 5.3 to 174.0	29 pg/mL Interval 10.0 to 107.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Interleukin-8 (IL-8) - Pre-treatment, Pre Allergen Challenge	—	766 pg/mL Interval 138.0 to 1784.0	522 pg/mL Interval 8.5 to 2500.0

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-8 - Pre-treatment, Post Allergen Challenge	—	1300 pg/mL Interval 422.0 to 2500.0	1450 pg/mL Interval 549.0 to 2500.0

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-8 - 1 Week After Last Dose, Pre Allergen Challenge	—	720 pg/mL Interval 186.0 to 2500.0	609 pg/mL Interval 63.0 to 2366.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-8 - 1 Week After Last Dose, Post Allergen Challenge	—	1272 pg/mL Interval 284.0 to 2500.0	1270 pg/mL Interval 240.0 to 2500.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-8 - 4 Weeks After Last Dose, Pre Allergen Challenge	—	496 pg/mL Interval 68.0 to 2500.0	1012 pg/mL Interval 176.0 to 2500.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-8 - 4 Weeks After Last Dose, Post Allergen Challenge	—	1500 pg/mL Interval 783.0 to 2500.0	1304 pg/mL Interval 595.0 to 2500.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Interleukin-10 (IL-10) - Pre-treatment, Pre Allergen Challenge	—	0.57 pg/mL Interval 0.5 to 1.1	0.63 pg/mL Interval 0.5 to 2.6

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-10 - Pre-treatment, Post Allergen Challenge	—	0.86 pg/mL Interval 0.5 to 32.0	0.68 pg/mL Interval 0.5 to 1.7

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-10 - 1 Week After Last Dose, Pre Allergen Challenge	—	0.60 pg/mL Interval 0.5 to 2.5	0.75 pg/mL Interval 0.5 to 34.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-10 - 1 Week After Last Dose, Post Allergen Challenge	—	0.79 pg/mL Interval 0.5 to 53.0	0.82 pg/mL Interval 0.5 to 3.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-10 - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.54 pg/mL Interval 0.5 to 0.9	0.95 pg/mL Interval 0.5 to 17.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-10 - 4 Weeks After Last Dose, Post Allergen Challenge	—	0.68 pg/mL Interval 0.5 to 1.9	0.67 pg/mL Interval 0.5 to 5.7

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Interleukin-13 (IL-13) - Pre-treatment, Pre Allergen Challenge	—	1.3 pg/mL Interval 1.2 to 3.6	1.4 pg/mL Interval 1.2 to 3.8

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-13 - Pre-treatment, Post Allergen Challenge	—	3.0 pg/mL Interval 1.2 to 25.0	3.1 pg/mL Interval 1.2 to 9.2

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-13 - 1 Week After Last Dose, Pre Allergen Challenge	—	1.3 pg/mL Interval 1.2 to 1.9	1.8 pg/mL Interval 1.2 to 8.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-13 - 1 Week After Last Dose, Post Allergen Challenge	—	3.0 pg/mL Interval 1.2 to 8.3	2.8 pg/mL Interval 1.2 to 20.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-13 - 4 Weeks After Last Dose, Pre Allergen Challenge	—	1.3 pg/mL Interval 1.2 to 2.1	1.6 pg/mL Interval 1.2 to 6.5

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, IL-13 - 4 Weeks After Last Dose, Post Allergen Challenge	—	2.5 pg/mL Interval 1.2 to 11.0	3.1 pg/mL Interval 1.2 to 17.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Total Cells/g - Pre-treatment, Pre Allergen Challenge	—	2.7 Cell count/g Interval 1.3 to 6.8	2.7 Cell count/g Interval 0.67 to 14.0

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Total Cells/g - Pre-treatment, Post Allergen Challenge	—	5.0 Cell count/g Interval 1.1 to 35.0	3.5 Cell count/g Interval 0.25 to 7.9

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Total Cells/g - 1 Week After Last Dose, Pre Allergen Challenge	—	3.7 Cell count/g Interval 0.84 to 16.0	3.0 Cell count/g Interval 0.95 to 20.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Total Cells/g - 1 Week After Last Dose, Post Allergen Challenge	—	5.0 Cell count/g Interval 1.9 to 19.0	4.2 Cell count/g Interval 0.55 to 18.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Total Cells/g - 4 Weeks After Last Dose, Pre Allergen Challenge	—	1.9 Cell count/g Interval 0.29 to 9.4	2.6 Cell count/g Interval 0.58 to 12.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Total Cells/g - 4 Weeks After Last Dose, Post Allergen Challenge	—	5.2 Cell count/g Interval 2.2 to 15.0	4.0 Cell count/g Interval 1.2 to 12.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Eosinophils - Pre-treatment, Pre Allergen Challenge	—	0.13 10^6 cells/g Interval 0.015 to 0.46	0.12 10^6 cells/g Interval 0.008 to 3.7

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Eosinophils - Pre-treatment, Post Allergen Challenge	—	0.64 10^6 cells/g Interval 0.008 to 6.5	0.81 10^6 cells/g Interval 0.023 to 3.0

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Eosinophils - 1 Week After Last Dose, Pre Allergen Challenge	—	0.18 10^6 cells/g Interval 0.033 to 2.1	0.23 10^6 cells/g Interval 0.008 to 2.8

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Eosinophils - 1 Week After Last Dose, Post Allergen Challenge	—	0.94 10^6 cells/g Interval 0.12 to 3.8	0.82 10^6 cells/g Interval 0.066 to 6.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Eosinophils - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.13 10^6 cells/g Interval 0.009 to 2.2	0.21 10^6 cells/g Interval 0.032 to 1.1

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Eosinophils - 4 Weeks After Last Dose, Post Allergen Challenge	—	1.0 10^6 cells/g Interval 0.2 to 5.8	0.96 10^6 cells/g Interval 0.13 to 4.6

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Neutrophils - Pre-treatment, Pre Allergen Challenge	—	0.75 10^6 cells/g Interval 0.026 to 4.2	0.93 10^6 cells/g Interval 0.026 to 10.0

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Neutrophils - Pre-treatment, Post Allergen Challenge	—	1.9 10^6 cells/g Interval 0.45 to 25.0	1.5 10^6 cells/g Interval 0.061 to 4.1

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Neutrophils - 1 Week After Last Dose, Pre Allergen Challenge	—	1.5 10^6 cells/g Interval 0.065 to 15.0	0.91 10^6 cells/g Interval 0.026 to 17.0

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Neutrophils - 1 Week After Last Dose, Post Allergen Challenge	—	2.1 10^6 cells/g Interval 0.36 to 9.1	1.7 10^6 cells/g Interval 0.22 to 15.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Neutrophils - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.80 10^6 cells/g Interval 0.097 to 7.5	1.3 10^6 cells/g Interval 0.072 to 9.3

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Neutrophils - 4 Weeks After Last Dose, Post Allergen Challenge	—	2.6 10^6 cells/g Interval 0.81 to 11.0	1.6 10^6 cells/g Interval 0.4 to 7.8

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Macrophages - Pre-treatment, Pre Allergen Challenge	—	1.1 10^6 cells/g Interval 0.29 to 2.2	0.59 10^6 cells/g Interval 0.004 to 3.7

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Macrophages - Pre-treatment, Post Allergen Challenge	—	1.1 10^6 cells/g Interval 0.13 to 4.9	0.60 10^6 cells/g Interval 0.1 to 2.1

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Macrophages - 1 Week After Last Dose, Pre Allergen Challenge	—	0.80 10^6 cells/g Interval 0.088 to 3.1	0.36 10^6 cells/g Interval 0.004 to 2.4

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Macrophages - 1 Week After Last Dose, Post Allergen Challenge	—	1.0 10^6 cells/g Interval 0.2 to 5.2	0.77 10^6 cells/g Interval 0.12 to 3.0

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Macrophages - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.47 10^6 cells/g Interval 0.004 to 1.9	0.58 10^6 cells/g Interval 0.22 to 1.6

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Macrophages - 4 Weeks After Last Dose, Post Allergen Challenge	—	0.56 10^6 cells/g Interval 0.087 to 1.8	0.74 10^6 cells/g Interval 0.083 to 4.0

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Lymphocytes - Pre-treatment, Pre Allergen Challenge	—	0.004 10^6 cells/g Interval 0.002 to 0.027	0.004 10^6 cells/g Interval 0.002 to 0.059

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Lymphocytes - Pre-treatment, Post Allergen Challenge	—	0.008 10^6 cells/g Interval 0.002 to 0.086	0.004 10^6 cells/g Interval 0.002 to 0.06

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Lymphocytes - 1 Week After Last Dose, Pre Allergen Challenge	—	0.002 10^6 cells/g Interval 0.002 to 0.016	0.003 10^6 cells/g Interval 0.002 to 0.046

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Lymphocytes - 1 Week After Last Dose, Post Allergen Challenge	—	0.003 10^6 cells/g Interval 0.002 to 0.04	0.003 10^6 cells/g Interval 0.002 to 0.045

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Lymphocytes - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.005 10^6 cells/g Interval 0.002 to 0.035	0.005 10^6 cells/g Interval 0.002 to 0.036

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Lymphocytes - 4 Weeks After Last Dose, Post Allergen Challenge	—	0.005 10^6 cells/g Interval 0.002 to 0.049	0.003 10^6 cells/g Interval 0.002 to 0.012

SECONDARY outcome

Timeframe: Pre-treatment, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=12 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Epithelial Cells - Pre-treatment, Pre Allergen Challenge	—	0.045 10^6 cells/g Interval 0.001 to 0.29	0.053 10^6 cells/g Interval 0.001 to 0.59

SECONDARY outcome

Timeframe: Pre-treatment, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Epithelial Cells - Pre-treatment, Post Allergen Challenge	—	0.078 10^6 cells/g Interval 0.001 to 3.5	0.073 10^6 cells/g Interval 0.001 to 0.35

SECONDARY outcome

Timeframe: 1 week after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=19 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Epithelial Cells - 1 Week After Last Dose, Pre Allergen Challenge	—	0.11 10^6 cells/g Interval 0.008 to 0.39	0.045 10^6 cells/g Interval 0.001 to 1.4

SECONDARY outcome

Timeframe: 1 week after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=17 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=17 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Epithelial Cells - 1 Week After Last Dose, Post Allergen Challenge	—	0.067 10^6 cells/g Interval 0.001 to 0.56	0.071 10^6 cells/g Interval 0.001 to 0.47

SECONDARY outcome

Timeframe: 4 weeks after last dose, pre allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=16 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Epithelial Cells - 4 Weeks After Last Dose, Pre Allergen Challenge	—	0.045 10^6 cells/g Interval 0.005 to 0.2	0.054 10^6 cells/g Interval 0.001 to 0.43

SECONDARY outcome

Timeframe: 4 weeks after last dose, post allergen challenge

Population: There were 6 AZD8848 nasal spray 30 μg subjects and 3 placebo subjects participated in the Pilot part only that they did not have outcome measure collected. The number of participants analyzed for each outcome measure were subset of the subjects who participated in the Main part and also provided data for that measure.

Outcome measures

Outcome measures
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg n=13 Participants AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo n=16 Participants Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Sputum Cellularity and Cytokines, Epithelial Cells - 4 Weeks After Last Dose, Post Allergen Challenge	—	0.037 10^6 cells/g Interval 0.001 to 0.17	0.082 10^6 cells/g Interval 0.018 to 0.24

Adverse Events

AZD8848, 30 μg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

AZD8848, 60 μg

Serious events: 0 serious events

Other events: 22 other events

Deaths: 0 deaths

Placebo

Serious events: 1 serious events

Other events: 24 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Infections and infestations Tonsillitis Bacterial	0.00% 0/6	0.00% 0/26	3.6% 1/28

Other adverse events

Other adverse events
Measure	AZD8848, 30 μg AZD8848 nasal spray, 30 μg, one spray in the left nostril once weekly. Pilot part.	AZD8848, 60 μg AZD8848 nasal spray, 60 μg, one spray of 30 μg per nostril once weekly. Main part.	Placebo Placebo nasal spray, one spray in the left nostril (Pilot part) or per nostril (Main part) once weekly.
Ear and labyrinth disorders TINNITUS	16.7% 1/6	0.00% 0/26	3.6% 1/28
Eye disorders Eye Pruritus	0.00% 0/6	0.00% 0/26	7.1% 2/28
Eye disorders LACRIMATION INCREASED	0.00% 0/6	0.00% 0/26	7.1% 2/28
Eye disorders EYE SWELLING	16.7% 1/6	0.00% 0/26	0.00% 0/28
Gastrointestinal disorders Dysphagia	16.7% 1/6	0.00% 0/26	0.00% 0/28
Gastrointestinal disorders GLOSSODYNIA	16.7% 1/6	0.00% 0/26	0.00% 0/28
Gastrointestinal disorders SWOLLEN TONGUE	16.7% 1/6	0.00% 0/26	0.00% 0/28
General disorders Pain	0.00% 0/6	3.8% 1/26	7.1% 2/28
General disorders CHEST DISCOMFORT	0.00% 0/6	7.7% 2/26	7.1% 2/28
General disorders PYREXIA	33.3% 2/6	15.4% 4/26	7.1% 2/28
Immune system disorders ALLERGY TO ARTHROPOD BITE	0.00% 0/6	7.7% 2/26	0.00% 0/28
Infections and infestations NASAL VESTIBULITIS	16.7% 1/6	0.00% 0/26	0.00% 0/28
Infections and infestations RHINITIS	0.00% 0/6	7.7% 2/26	17.9% 5/28
Infections and infestations NASOPHARYNGITIS	16.7% 1/6	7.7% 2/26	14.3% 4/28
Injury, poisoning and procedural complications FACE INJURY	16.7% 1/6	0.00% 0/26	0.00% 0/28
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	16.7% 1/6	0.00% 0/26	0.00% 0/28
Musculoskeletal and connective tissue disorders BACK PAIN	16.7% 1/6	3.8% 1/26	0.00% 0/28
Musculoskeletal and connective tissue disorders ARTHRALGIA	16.7% 1/6	11.5% 3/26	3.6% 1/28
Nervous system disorders DYSGEUSIA	16.7% 1/6	0.00% 0/26	0.00% 0/28
Nervous system disorders LETHARGY	16.7% 1/6	0.00% 0/26	0.00% 0/28
Nervous system disorders DIZZINESS	16.7% 1/6	3.8% 1/26	0.00% 0/28
Nervous system disorders HEADACHE	66.7% 4/6	57.7% 15/26	42.9% 12/28
Respiratory, thoracic and mediastinal disorders SPUTUM DISCOLOURED	0.00% 0/6	0.00% 0/26	7.1% 2/28
Respiratory, thoracic and mediastinal disorders NASAL INFLAMMATION	16.7% 1/6	0.00% 0/26	0.00% 0/28
Respiratory, thoracic and mediastinal disorders NASAL MUCOSAL DISORDER	50.0% 3/6	0.00% 0/26	0.00% 0/28
Respiratory, thoracic and mediastinal disorders NASAL SEPTUM ULCERATION	33.3% 2/6	0.00% 0/26	0.00% 0/28
Respiratory, thoracic and mediastinal disorders UPPER AIRWAY OBSTRUCTION	66.7% 4/6	0.00% 0/26	0.00% 0/28
Respiratory, thoracic and mediastinal disorders NASAL DISCOMFORT	50.0% 3/6	3.8% 1/26	14.3% 4/28
Respiratory, thoracic and mediastinal disorders WHEEZING	16.7% 1/6	3.8% 1/26	14.3% 4/28
Respiratory, thoracic and mediastinal disorders THROAT IRRITATION	16.7% 1/6	3.8% 1/26	0.00% 0/28
Respiratory, thoracic and mediastinal disorders COUGH	16.7% 1/6	7.7% 2/26	25.0% 7/28
Respiratory, thoracic and mediastinal disorders RHINORRHOEA	66.7% 4/6	7.7% 2/26	14.3% 4/28
Respiratory, thoracic and mediastinal disorders NASAL DRYNESS	0.00% 0/6	7.7% 2/26	7.1% 2/28
Respiratory, thoracic and mediastinal disorders SNEEZING	33.3% 2/6	7.7% 2/26	3.6% 1/28
Respiratory, thoracic and mediastinal disorders EPISTAXIS	66.7% 4/6	11.5% 3/26	7.1% 2/28
Respiratory, thoracic and mediastinal disorders NASAL CONGESTION	0.00% 0/6	11.5% 3/26	7.1% 2/28
Respiratory, thoracic and mediastinal disorders ASTHMA	0.00% 0/6	15.4% 4/26	14.3% 4/28
Respiratory, thoracic and mediastinal disorders OROPHARYNGEAL PAIN	33.3% 2/6	19.2% 5/26	28.6% 8/28
Skin and subcutaneous tissue disorders ERYTHEMA	33.3% 2/6	0.00% 0/26	3.6% 1/28
Skin and subcutaneous tissue disorders RASH	16.7% 1/6	7.7% 2/26	7.1% 2/28

Additional Information

Gerard Lynch

AstraZeneca

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed. The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ
Publication restrictions are in place

Restriction type: OTHER